Sanofi India Ltd

Sanofi India Ltd

Sanofi India Ltd has announced its Q2 2026 financial results, reporting 8% domestic net sales growth and 6% total net sales growth compared to Q2 2025. The company's insulin portfolio delivered double-digit growth of 14% for the second consecutive quarter, driven by strong performance of Lantus, Toujeo, and Apidra. Profits before tax and exceptional items increased 19% to INR 112 crores, with profit before tax as a percentage of net sales improving to 27% in Q2 2026.

Sanofi India Ltd

Sanofi India Ltd has announced its Q2 2026 financial results, with domestic net sales growth of 8% and total net sales growth of 6% compared to the second quarter of 2025. The company's insulin portfolio delivered double-digit growth of 14% for the second consecutive quarter, driven by strong performance of Lantus, Toujeo, and Apidra. Profits before tax and exceptional items increased 19% to INR 112 crores, with profit before tax as a percentage of net sales improving to 27% in Q2 2026.

Sanofi India Ltd

Sanofi India Ltd announced its financial results for Q2 2026, reporting domestic net sales growth of 8% and total net sales growth of 6% compared to Q2 2025. The Insulin portfolio delivered double-digit growth of 14% for the second consecutive quarter, driven by Lantus, Toujeo, and Apidra. Profit before tax and exceptional items increased 19% to INR 112 crores, with profit before tax as a percentage of net sales improving to 27% in Q2 2026.

Sanofi India Ltd

Sanofi India Ltd has announced its Q2 2026 financial results, reporting 8% domestic net sales growth and 6% total net sales growth compared to Q2 2025. The company's insulin portfolio delivered double-digit growth of 14% for the second consecutive quarter, driven by strong performance of Lantus, Toujeo, and Apidra. Profits before tax and exceptional items increased 19% to INR 112 crores, with profit before tax as a percentage of net sales improving to 27%.

Sanofi India Ltd

Sanofi India Ltd reported its unaudited financial results for the quarter and half year ended 30th June 2026, with domestic net sales growth of 8% and total net sales growth of 6% compared to the second quarter of 2025. The company's profits before tax and exceptional items increased 19% to INR 112 crores, with a profit before tax as a percentage of net sales improving to 27% in Q2 2026.

Sanofi India Ltd

Sanofi India Ltd announced a change in senior management personnel, with Mr. Nakul Verma ceasing to be a Senior Management Personnel of the Company, effective July 31, 2026, due to his transition to another role within the Sanofi group.

Sanofi India Ltd

Sanofi India Ltd will hold an investor/analysts call on 5th August 2026 to discuss unaudited financial results for the quarter and half year ended 30th June 2026.

Sanofi India Ltd

Sanofi India Ltd announces the resignation of Mr. Rachid Ayari as Whole Time Director, Chief Financial Officer, and Key Managerial Personnel, effective September 30, 2026. The company appreciates his contributions and is in the process of identifying a suitable candidate for the CFO position.

Sanofi India Ltd

Sanofi India Ltd's Chief Financial Officer (CFO), Mr. Rachid Ayari, has resigned from his position, effective September 30, 2026, to transition to another role within the Sanofi group.

Sanofi India Ltd

Sanofi India Ltd announces change in management with Mr. Rachid Ayari stepping down as Whole Time Director, Chief Financial Officer, and Key Managerial Personnel effective September 30, 2026, due to transition to another role within the Sanofi group.

Sanofi India Ltd

Sanofi India Ltd announced that Mr. Rachid Ayari, Whole Time Director, Chief Financial Officer and Key Managerial Personnel, will step down from his current role effective September 30, 2026, to transition to another role within the Sanofi group. The company is in the process of identifying a suitable candidate for the position of Chief Financial Officer.